Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. ("FFF"). Molluscum is a highly contagious viral skin disease that affects approximately six million people ? primarily children ?

in the United States. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites (objects that carry the disease like toys, towels or wet surfaces) and can spread to other parts of the body or to other people, including siblings.

The lesions can be found on most areas of the body and may carry substantial social stigma. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years. YCANTH is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum.

YCANTH? is the only product approved by the FDA to treat molluscum ? a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children.